TaffiX® Nasal Powder forms an Effective Barrier against SARS-CoV-2

Barbara J Mann, G Brett Moreau, Tair Lapidot and Dalia Megiddo
Additional contact information
G Brett Moreau: University of Virginia School of Medicine, Department of Medicine, Division of Infectious Diseases and International Health, Charlottesville, VA, USA
Dalia Megiddo: Nasus Pharma, 29 Harakevet St, Tel Aviv, Israel

Biomedical Journal of Scientific & Technical Research, 2021, vol. 33, issue 3, 25843-25845

Abstract: TaffiX® is a personal anti-viral nasal powder that is commercially available in Israel and Europe...

Keywords: Infectious Diseases; Viral Fever; Quantitative Research; SARS-CoV-2; COVID-19 (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://biomedres.us/pdfs/BJSTR.MS.ID.005405.pdf (application/pdf)
https://biomedres.us/fulltexts/BJSTR.MS.ID.005405.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abf:journl:v:33:y:2021:i:3:p:25843-25845

DOI: 10.26717/BJSTR.2021.33.005405

Access Statistics for this article

Biomedical Journal of Scientific & Technical Research is currently edited by Robert Thomas

More articles in Biomedical Journal of Scientific & Technical Research from Biomedical Research Network+, LLC
Bibliographic data for series maintained by Angela Roy ().